Novo Nordisk Reaches Settlement with Texas Pharmacy Over Compounded Ozempic Drugs

The legal dispute involving Novo Nordisk, the manufacturer of the weight loss drug Ozempic, has reached a resolution with a Houston-area pharmacy accused of selling compounded, non-FDA-approved medications. These medications were alleged to contain semaglutide, Ozempic’s key ingredient. According to the report, the pharmacy has agreed to cease marketing these compounded semaglutide drugs following the settlement. This case underscores the ongoing legal challenges pharmaceutical companies face in protecting their proprietary drugs from unlicensed compounding and distribution. For additional context, Novo Nordisk’s vigilance in maintaining the integrity and legality of its products is reflective of broader industry trends as pharmaceutical companies combat unauthorized reproduction of their formulations.